Methylgene announces the initiation of a Phase 2 trial of MGCD0103
Montreal, Quebec. June 25, 2008 – MethylGene Inc. (TSX: MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.